Compare Adaptive Biotechnologies Corp (ADPT) vs Royal Bank of Canada (RY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Royal Bank of Canada — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Royal Bank of Canada trades at $205.63 (market cap $290.60B). The key difference: Royal Bank of Canada is far larger — about 87.3× Adaptive Biotechnologies Corp's market cap, and Royal Bank of Canada pays a 2.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | RY | |
|---|---|---|
Market Cap | $3.33B | $290.60B |
Sector | Health | Financials |
52-Week High | $22.37 | $209.07 |
52-Week Low | $10.24 | $128.46 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Royal Bank of Canada (RY) trades at $209.07, up 2.09% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 31.85% net income margin and 17.17% ROE, supported by a $1.76 quarterly dividend and a share repurchase program. Revenue grew to $66.53B in 2025, and cash flow trends indicate improving operational strength.
RY presents a solid investment case with consistent profitability and shareholder returns, though valuation metrics like a P/E of 19.2 and P/B of 3.17 suggest premium pricing. Risks include economic sensitivity and high debt levels, but analyst consensus leans positive with 43% buy ratings. The outlook remains favorable if earnings growth persists amid macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
